It has long been known that the beneficial effects of opiate analgesia are tempered by rapidly developing tolerance to and dependence on the narcotic. Nevertheless, there are several potential mechanisms to circumvent opiate addition and maintain potent analgesia. It is now known that mu, delta, and kappa opioid receptor types can all mediate the analgesic response. Although mu receptor activation has the potential of addiction liability, recently it has been shown that some opioid compounds with lower efficacy at the mu receptor can maintain potent analgesic activity while possessing a much reduced addiction liability. Furthermore, low efficacy in agonists have been shown to have potential for the treatment of drug abuse. Using the mu receptor-containing neuroblastonia cell line SH-SY5Y we can measure receptor binding affinity and a biochemical measure of receptor activity (inhibition of cAMP accumulation) under identical conditions. Relative efficacies can be calculated based upon the definition that relative efficacy equals relative activity at equal receptor occupancy. This system can provide a simple in vitro screen for opiates with low abuse potential. General information about receptor-effector coupling for mu opioid receptors will also be gained by treatment of cells with beta-CNA to inactivate the receptors, pertussis toxin to inactivate the G-protein G-i, and high potassium or veratridine to depolarize the cell. Another mechanism to circumvent opiate addiction is the use of another receptor type. Although it has been shown that delta receptors can mediate analgesia, addiction through this receptor has not been well characterized. In addition, there has been recent interest in the characterization of delta subtypes and their molecular interactions with mu receptors. Delta receptors may have a modulatory role in opiate analgesia. Because SH-SY5Y cells contain both mu and delta receptors, the delta receptor subtype can be characterized, and interactions between mu and delta receptors can be studied in single cells. Studies of mu efficacies, delta receptors, and mu-delta interactions should lead to a better understanding of opioid actions and aid in the development of analgesics with low abuse potential.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA006682-04
Application #
2118884
Study Section
Drug Abuse Biomedical Research Review Committee (DABR)
Project Start
1990-09-30
Project End
1996-04-30
Budget Start
1994-05-01
Budget End
1995-04-30
Support Year
4
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Sri International
Department
Type
DUNS #
City
Menlo Park
State
CA
Country
United States
Zip Code
94025
Khroyan, Taline V; Polgar, Willma E; Orduna, Juan et al. (2007) Anti-nociceptive and anti-allodynic effects of a high affinity NOP hexapeptide [Ac-RY(3-Cl)YRWR-NH2] (Syn 1020) in rodents. Eur J Pharmacol 560:29-35
Zaveri, Naunihal T; Waleh, Nahid; Toll, Lawrence (2006) Regulation of the prepronociceptin gene and its effect on neuronal differentiation. Gene 384:27-36
Jong, Ling; Zaveri, Nurulain; Toll, Lawrence (2004) The design and synthesis of a novel quinolizidine template for potent opioid and opioid receptor-like (ORL1, NOP) receptor ligands. Bioorg Med Chem Lett 14:181-5
Judd, A K; Tuttle, D J; Jones, R W et al. (2004) Structure-activity studies on high affinity NOP-active hexapeptides. J Pept Res 64:87-94
Judd, A K; Kaushanskaya, A; Tuttle, D J et al. (2003) N-terminal modifications leading to peptide ORL1 partial agonists and antagonists. J Pept Res 62:191-8
Zaveri, Naunihal T; Green, Christopher J; Polgar, Willma E et al. (2002) Regulation of transcription of the human prepronociceptin gene by Sp1. Gene 290:45-52
Zaveri, N; Polgar, W E; Olsen, C M et al. (2001) Characterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptors. Eur J Pharmacol 428:29-36
Burnside, J L; Rodriguez, L; Toll, L (2000) Species differences in the efficacy of compounds at the nociceptin receptor (ORL1). Peptides 21:1147-54
Zaveri, N T; Green, C J; Toll, L (2000) Transcriptional regulation of the human prepronociceptin gene. Biochem Biophys Res Commun 276:710-7
Toll, L; Polgar, W E; Auh, J S (1997) Characterization of the delta-opioid receptor found in SH-SY5Y neuroblastoma cells. Eur J Pharmacol 323:261-7

Showing the most recent 10 out of 20 publications